Assigning value to medical algorithms: Implications for personalized medicine

Personalized Medicine

Volumn 10, Issue 6, 2013, Pages 577-588

  Hornberger, John ^a,b  

^a Cedar Associates   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

affordability; clinical practice; genomics; medical algorithms; personalized medicine; public participation

Indexed keywords

ALGORITHM; CLINICAL PRACTICE; DATA COLLECTION METHOD; DIAGNOSTIC IMAGING; GENETIC ALGORITHM; HUMAN; PERSONALIZED MEDICINE; PHYSICAL EXAMINATION; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SOCIAL WELFARE; THEORY; TREATMENT PLANNING;

EID: 84881411894     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.13.55     Document Type: Review

References (50)

1. Kuehn BM. 1000 Genomes Project promises closer look at variation in human genome.JAMA 300(23), 2715 (2008
2. Collins FS, McKusick VA. Implications of the Human Genome Project for medical science. JAMA 285(5), 540-544 (2001
3. Hornberger J, Doberne J, Chien R. Laboratory-developed test- SynFRAME: An approach for assessing laboratory-developed tests synthesized from prior appraisal frameworks. Genet. Test. Mol. Biomarkers 16(6), 605-614 (2012
4. Doyle DJ, Jarvis BA, Ruskin KJ, Engel TP. Medical computing over the World Wide Web: Use of forms and CGI scripts for constructing medical algorithm web pages. J. Clin. Eng. 22(6), 419-434 (1997
5. Roshanov PS, Fernandes N, Wilczynski JM et al. Features of effective computerised clinical decision support systems: Meta-regression of 162 randomised trials. BMJ 346, f657 (2013
6. de Backere F, Moens H, Steurbaut K, Colpaert K, Decruyenaere J, de Turck F. Towards automated generation and execution of clinical guidelines: Engine design and implementation through the ICU Modified Schofield use case. Comput. Biol. Med. 42(8), 793-805 (2012
7. Kolesa P, Spidlen J, Zvárová J. Obstacles to implementing an execution engine for clinical guidelines formalized in GLIF. Stud. Health Technol. Inform. 116, 563-568 (2005
8. Ram P, Berg D, Tu S et al. Executing clinical practice guidelines using the SAGE execution engine. Stud. Health Technol. Inform. 107(Pt 1), 251-255 (2004
9. Fullerton SM, Wolf WA, Brothers KB et al. Return of individual research results from genome-wide association studies: Experience of the Electronic Medical Records and Genomics (eMERGE) Network. Genet. Med. 14(4), 424-431 (2012
10. McCarty CA, Chisholm RL, Chute CG et al. The eMERGE Network: A consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med. Genomics 4, 13 (2011
11. Leach-Kemon K, Chou DP, Schneider MT et al. The global financial crisis has led to a slowdown in growth of funding to improve health in many developing countries. Health Aff. (Millwood) 31(1), 228-235 (2012
12. Horton R. The global financial crisis: An acute threat to health. Lancet 373(9661), 355-356 (2009
13. Mechanic D. Rethinking medical professionalism: The role of information technology and practice innovations. Milbank Q. 86(2), 327-358 (2008
14. Doran T, Fullwood C, Gravelle H et al. Pay-for-performance programs in family practices in the United Kingdom. N. Engl. J. Med. 355(4), 375-384 (2006
15. Kmietowicz Z. New GP contract: Modernisation or miscalculation? BMJ 333(7580), 1192 (2006
16. Hornberger J, Thom D, MaCurdy T. Effects of a self-administered previsit questionnaire to enhance awareness of patients' concerns in primary care. J. Gen. Intern. Med. 12(10), 597-606 (1997
17. Levey AS, Coresh J, Greene T et al. Expressing the Modification of Diet in Renal Disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin. Chem. 53(4), 766-772 (2007
18. Kahneman D. Thinking, Fast and Slow (1st Edition). Farrar, Straus and Giroux, NY, USA (2011
19. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 97(18), 1837-1847 (1998
20. Tu SW, Campbell JR, Glasgow J et al. The SAGE guideline model: Achievements and overview. J. Am. Med. Inform. Assoc. 14(5), 589-598 (2007
21. Quaglini S. Compliance with clinical practice guidelines. Stud. Health Technol. Inform. 139, 160-179 (2008
22. Eisenberg JM. Globalize the evidence, localize the decision: Evidence-based medicine and international diversity. Health Aff. (Millwood) 21(3), 166-168 (2002
23. Hornberger J. Comparative effectiveness in personalized medicine- clearly defining the intended use population. Value Health 16(4), 696 (2013
24. Greenberg D, Rosen AB, Wacht O, Palmer J, Neumann PJ. A bibliometric review of cost-effectiveness analyses in the economic and medical literature: 1976-2006. Med. Decis. Making 30(3), 320-327 (2010
25. Gudgeon JM, Williams JL, Burt RW, Samowitz WS, Snow GL, Williams MS. Lynch syndrome screening implementation: Business analysis by a healthcare system. Am. J. Manag. Care 17(8), e288-e300 (2011
26. Hornberger J, Cosler LE, Lyman GH. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am. J. Manag. Care 11(5), 313-324 (2005
27. Klang SH, Hammerman A, Liebermann N, Efrat N, Doberne J, Hornberger J. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization.Value Health 13(4), 381-387 (2010
28. Hornberger J, Lyman GH, Chien R. Economic implications of 21-gene recurrence score assay: US multicenter experience. J. Clin. Oncol. 28(22), e382; author reply e383 (2010
29. Hornberger J, Alvarado MD, Rebecca C, Gutierrez HR, Yu TM, Gradishar WJ. Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: A systematic review. J. Natl Cancer Inst. 104(14), 1068-1079 (2012
30. Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices- overview: A report of the ISPOR-SMDM Modeling Good Research Practices Task Force- 1. Value Health 15(6), 796-803 (2012
31. Smith A, Jenkins AH. Adam Smith Today: An Inquiry into the Nature and Causes of the Wealth of Nations. RR Smith, NY, USA (1948
32. Dobb M. Theories of Value and Distribution Since Adam Smith; Ideology and Economic Theory. Cambridge University Press, Cambridge, UK (1973
33. Arrow KJ. Uncertainty and the welfare economics of medical care. 1963. J. Health Polit. Policy Law 26(5), 851-883 (2001
34. Arrow KJ. Reflections on the reflections. J. Health Polit. Policy Law 26(5), 1197-1203 (2001
35. Hammer PJ, Haas-Wilson D, Sage WM. Kenneth Arrow and the changing economics of health care: 'Why Arrow? Why now?'. J. Health Polit. Policy Law 26(5), 835-849 (2001
36. Junankar PN. Marx's Economics. Philip Allan Publishers, Oxfordshire, UK (1982
37. Baldwin J. The Medieval theories of the just price: Romanists, Canonists, and Theologians in the twelfth and thirteenth centuries. Trans. Amer. Philosophical Soc. 49, 1-92 (1959
38. Hsiao WC, Braun P, Yntema D, Becker ER. Estimating physicians' work for a resource-based relative-value scale. N. Engl. J. Med. 319(13), 835-841 (1988
39. Light DW, Lexchin JR. Pharmaceutical research and development: What do we get for all that money? BMJ 345, e4348 (2012
40. Garber AM. Cost-effectiveness and evidence evaluation as criteria for coverage policy.Health Aff. (Millwood) Suppl. Web Exclusives, W4-284-296 (2004
41. Thokala P, Duenas A. Multiple criteria decision analysis for health technology assessment. Value Health 15(8), 1172-1181 (2012
42. Olsen JA, Smith RD. Theory versus practice: A review of 'willingness-to-pay' in health and health care. Health Econ. 10(1), 39-52 (2001
43. Brannigan M. Oregon's experiment. Health Care Anal. 1(1), 15-32 (1993
44. Schneeweiss S, Maclure M, Dormuth C, Avorn J. Pharmaceutical cost containment with reference-based pricing: Time for refinements. CMAJ 167(11), 1250-1251 (2002
45. Blackstone EA, Fuhr JP Jr. Innovation and competition: Will biosimilars succeed? The creation of an FDA approval pathway for biosimilars is complex and fraught with hazard. Yes, innovation and market competition are at stake. But so are efficacy and patient safety. Biotechnol. Healthc. 9(1), 24-27 (2012
46. Woodcock J, Wosinska M. Economic and technological drivers of generic sterile injectable drug shortages. Clin. Pharmacol. Ther. 93(2), 170-176 (2013
47. Boivin A, Currie K, Fervers B et al. Patient and public involvement in clinical guidelines: International experiences and future perspectives. Qual. Saf. Health Care 19(5), e22 (2010
48. Legare F, Boivin A, Van Der Weijden T et al. Patient and public involvement in clinical practice guidelines: A knowledge synthesis of existing programs. Med. Decis. Making 31(6), e45-e74 (2011
49. Van De Bovenkamp HM, Trappenburg MJ, Grit KJ. Patient participation in collective healthcare decision making: The Dutch model. Health Expect. 13(1), 73-85 (2010
50. Jacobs AK, Kushner FG, Ettinger SM, Guyton RA, Anderson JL, Ohman EM et al. ACCF/AHA clinical practice guideline methodology summit report: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 127(2), 268-310 (2013